Contact SCGE




SCGE Consortium Home   |  About SCGE   |  Contact Us   |  Citing the Toolkit   |  License  

Experiment: Testing newly discovered Biggie Phage editors in human cells

PI:   Jennifer A Doudna, PhD  Jillian Banfield, PhD 
 
 

Editing Assay: - A plasmid expressing CasΦ and gRNA tranfected into stable GFP cell line in triplciate. 72 hours post transfection, GFP negative cells were quantified by flow cytometry

Filter Results ..
  Editors
 CasΦ-1
 CasΦ-2
 CasΦ-3
  Guide Target Locus
 eGFP
 non-targeting
  Guides
 Cas12j-GFP10 (CasΦ-2)
 Cas12j-GFP10 (CasΦ-3)
 Cas12j-GFP11 (CasΦ-3)
 Cas12j-GFP12 (CasΦ-3)
 Cas12j-GFP13 (CasΦ-3)
 Cas12j-GFP14 (CasΦ-2)
 Cas12j-GFP14 (CasΦ-3)
 Cas12j-GFP15 (CasΦ-1)
 Cas12j-GFP16 (CasΦ-1)
 Cas12j-GFP17 (CasΦ-1)
 Cas12j-GFP18 (CasΦ-1)
 Cas12j-GFP19 (CasΦ-1)
 Cas12j-GFP1 (CasΦ-1)
 Cas12j-GFP1 (CasΦ-2)
 Cas12j-GFP20 (CasΦ-1)
 Cas12j-GFP21 (CasΦ-1)
 Cas12j-GFP22 (CasΦ-1)
 Cas12j-GFP23 (CasΦ-1)
 Cas12j-GFP2 (CasΦ-1)
 Cas12j-GFP2 (CasΦ-2)
 Cas12j-GFP3 (CasΦ-1)
 Cas12j-GFP3 (CasΦ-2)
 Cas12j-GFP4 (CasΦ-1)
 Cas12j-GFP4 (CasΦ-2)
 Cas12j-GFP5 (CasΦ-1)
 Cas12j-GFP5 (CasΦ-2)
 Cas12j-GFP5 (CasΦ-3)
 Cas12j-GFP6 (CasΦ-2)
 Cas12j-GFP6 (CasΦ-3)
 Cas12j-GFP7 (CasΦ-2)
 Cas12j-GFP7 (CasΦ-3)
 Cas12j-GFP8 (CasΦ-2)
 Cas12j-GFP8 (CasΦ-3)
 Cas12j-GFP9 (CasΦ-2)
 Cas12j-GFP9 (CasΦ-3)
 SapI-GG stuffer (CasΦ-1)
 SapI-GG stuffer (CasΦ-2)
 SapI-GG stuffer (CasΦ-3)
Delivery Systems
 Lipofectamine 3000
Models
 HEK293-TgEF1a-eGFP-BSD
Sex
 Female
Result Types
 Editing Efficiency
Units
 % of GFP negative cells
  Vectors
 pPP394
 pPP441
 pPP444

Make a selection to highlight records on the chart:


Results

Testing_newly_discovered_Biggie_Phage_editors_in_human_cells
Condition Sex Editor Model Delivery System Target Locus Guide Vector Dosage Result Type Units Result/Mean Image
Cas12j-GFP1 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP1 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.90 0.97 0.8099999999999999 0.9199999999999999
Cas12j-GFP2 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP2 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.93 1.04 0.8699999999999999 0.8699999999999999
Cas12j-GFP3 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP3 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 1.16 1.6099999999999999 0.91 0.96
Cas12j-GFP4 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP4 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.91 0.96 0.76 1.0
Cas12j-GFP5 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP5 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.88 0.7799999999999999 0.8099999999999999 1.04
Cas12j-GFP15 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP15 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.95 1.05 0.9299999999999999 0.88
Cas12j-GFP16 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP16 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.90 0.8999999999999999 0.88 0.91
Cas12j-GFP17 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP17 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.93 0.8699999999999999 1.05 0.88
Cas12j-GFP18 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP18 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.96 1.1199999999999999 0.98 0.79
Cas12j-GFP19 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP19 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.94 0.86 1.0 0.97
Cas12j-GFP20 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP20 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.89 0.8999999999999999 0.9400000000000001 0.8200000000000001
Cas12j-GFP21 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP21 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 1.00 1.13 0.89 0.98
Cas12j-GFP22 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP22 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.90 0.79 1.0699999999999998 0.84
Cas12j-GFP23 (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP23 (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 1.02 1.02 1.0699999999999998 0.98
SapI-GG stuffer (CasΦ-1) Female CasΦ-1 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 non-targeting SapI-GG stuffer (CasΦ-1) pPP394 200 ng Editing Efficiency % of GFP negative cells 0.91 0.9299999999999999 1.02 0.79
Cas12j-GFP1 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP1 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 0.84 0.74 0.88 0.89
Cas12j-GFP2 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP2 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 2.01 2.19 1.77 2.06
Cas12j-GFP3 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP3 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 3.29 3.47 3.2099999999999995 3.2
Cas12j-GFP4 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP4 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 1.02 1.1900000000000002 1.0 0.88
Cas12j-GFP5 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP5 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 0.90 1.03 0.6799999999999999 0.9900000000000001
Cas12j-GFP6 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP6 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 12.90 14.099999999999998 12.8 11.799999999999999
Cas12j-GFP7 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP7 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 1.87 1.8800000000000001 1.6400000000000001 2.09
Cas12j-GFP8 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP8 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 33.50 32.7 34.699999999999996 33.1
Cas12j-GFP9 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP9 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 22.13 23.5 21.7 21.2
Cas12j-GFP10 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP10 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 1.12 1.28 1.0999999999999999 0.98
Cas12j-GFP14 (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP14 (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 2.15 2.13 2.08 2.2399999999999998
SapI-GG stuffer (CasΦ-2) Female CasΦ-2 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 non-targeting SapI-GG stuffer (CasΦ-2) pPP441 200 ng Editing Efficiency % of GFP negative cells 0.80 0.79 0.8200000000000001 0.8
Cas12j-GFP5 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP5 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 1.51 1.5699999999999998 1.3 1.66
Cas12j-GFP6 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP6 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 1.37 1.6400000000000001 1.21 1.27
Cas12j-GFP7 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP7 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 0.99 0.8699999999999999 1.04 1.06
Cas12j-GFP8 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP8 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 4.58 4.1000000000000005 4.760000000000001 4.87
Cas12j-GFP9 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP9 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 7.34 7.000000000000001 7.6499999999999995 7.359999999999999
Cas12j-GFP10 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP10 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 1.77 1.8599999999999999 1.73 1.71
Cas12j-GFP11 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP11 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 1.04 1.0 1.05 1.08
Cas12j-GFP12 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP12 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 0.96 1.2 0.79 0.8999999999999999
Cas12j-GFP13 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP13 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 1.01 1.02 1.17 0.84
Cas12j-GFP14 (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 eGFP Cas12j-GFP14 (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 0.79 0.8099999999999999 0.8200000000000001 0.75
SapI-GG stuffer (CasΦ-3) Female CasΦ-3 HEK293-TgEF1a-eGFP-BSD Lipofectamine 3000 non-targeting SapI-GG stuffer (CasΦ-3) pPP444 200 ng Editing Efficiency % of GFP negative cells 0.87 0.88 0.84 0.89


Publication Title
CRISPR-CasΦ from huge phages is a hypercompact genome editor. NCBI